Travere Therapeutics (TVTX) – Research Analysts’ Weekly Ratings Updates

Travere Therapeutics (NASDAQ: TVTX) recently received a number of ratings updates from brokerages and research firms:

• 4/14/2026 – Travere Therapeutics had its price target raised by Citigroup Inc. from $48.00 to $53.00. They now have a “buy” rating on the stock.
• 4/14/2026 – Travere Therapeutics was upgraded by Piper Sandler from “neutral” to “overweight”. They now have a $49.00 price target on the stock.
• 4/14/2026 – Travere Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $47.00 to $56.00. They now have a “buy” rating on the stock.
• 4/14/2026 – Travere Therapeutics had its price target raised by Wedbush from $39.00 to $44.00. They now have an “outperform” rating on the stock.
• 4/14/2026 – Travere Therapeutics had its price target raised by Guggenheim from $49.00 to $54.00. They now have a “buy” rating on the stock.
• 4/14/2026 – Travere Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $47.00 price target on the stock.
• 3/25/2026 – Travere Therapeutics had its price target lowered by JPMorgan Chase & Co. from $44.00 to $41.00. They now have an “overweight” rating on the stock.
• 2/21/2026 – Travere Therapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.

Insider Activity

In other news, Director Roy D. Baynes sold 32,750 shares of the firm’s stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $41.29, for a total transaction of $1,352,247.50. Following the completion of the transaction, the director owned 37,500 shares in the company, valued at $1,548,375. This trade represents a 46.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Sandra Calvin sold 21,977 shares of the stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $41.07, for a total transaction of $902,595.39. Following the completion of the transaction, the chief accounting officer directly owned 42,353 shares of the company’s stock, valued at approximately $1,739,437.71. The trade was a 34.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 514,069 shares of company stock valued at $18,092,672. 4.19% of the stock is owned by corporate insiders.

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.